NurExone moves towards human clinical trials, completes pre-IND meeting with FDA

Health Care, The Watchlist

NurExone Biologic Inc. (TSXV:NRX) has completed a pre-investigational new drug meeting with the U.S. FDA regarding its exotherapy product.

TSXV:NRX

1 min

NurExone Biologic Inc. (TSXV:NRX) (FSE:J90), a biopharmaceutical company developing biologically guided exosome therapy for patients with traumatic spinal cord injuries, has announced that it has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone’s first exotherapy product, after receiving a written response from the FDA on Aug. 29.

This is sponsored content issued on behalf of NurExone Biologic Inc., please see full disclaimer here.

Join the discussion: Find out what everybody’s saying about this stock on the NurExone Biologic Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

MindBio Therapeutics (CSE:MBIO) makes a major discovery about how psychedelic microdosing affects a patient’s speech.

Ventripoint Diagnostics (TSXV:VPT) achieved a milestone in its work to provide accurate volumetric cardiac measurements equivalent to MRI.

As a patient with BCG-Unresponsive NMIBC CIS, bladder removal is far from the only option on the table in 2024.

The TSX faced challenges as investors remained cautious, bracing for the upcoming US inflation data to gauge the Federal Reserve’s stance.